UK To Test Third Vaccine Dose In Immunocompromised People
Data From OCTAVE Study Show Low Response In 40% Of Patients After Two Doses
Initial results of the OCTAVE DUO study are expected later this year and will feed into the UK’s deployment of COVID-19 vaccines in people with weakened immune systems.
You may also be interested in...
Coronavirus Notebook: ‘No Urgent Need’ For Booster Vaccines, But EU & UK Advise Additional Doses In Immunocompromised
ExeVir Bio has begun a Phase Ib study of its neutralizing antibody XVR011, NRx Pharmaceuticals has reported promising results with aviptadil in improving lung function, and Meletios Therapeutics has raised funds to further the development of an antiviral that acts on the SARS-CoV-2 virus and infected host cells.
The mRNA-1273.214 vaccine will add to the UK’s armory for protecting people against coronavirus over the coming winter season.
New supply arrangements with the two firms are expected to offer greater protection to people in Europe as the autumn/winter season approaches. The EU’s health crisis preparedness body HERA has also identified its “top three health threats.”